sanofi

Expected R&D *milestones* in 2022

		H1 2022	*Comment*	*H2 2022*
Dupixent®	EoE	US/EU regulatory submissions	Achieved **US**	
	PN	US/EU regulatory submissions		
	CSU	Pivotal trial readout (Study B)	Study **negative**, program continues	
	CInDU			Pivotal trial readout
Oncology	amcenestrant 2/3L mBC	Pivotal trial readout	Study **negative**	
	SAR'245			Phase 3 decision
	Sarclisa® (1L MM)			Pivotal trial readout (IMROZ)
	Libtayo® (1L NSCLC CT combo)			US regulatory decision
Rare blood diseases	efanesoctocog alfa (HemA)	Pivotal trial readout	Study **positive**	US submission (mid-year)
	sutimlimab (CAD)	US regulatory decision	Achieved	
Rare diseases	olipudase alfa (ASMD)	JP regulatory decision (SAKIGAKE)	Achieved	US regulatory decision
Vaccines	nirsevimab (RSV)	EU submission	Achieved	US submission
	RSV Toddler			Pivotal trial decision
	COVID-19 recombinant	US/EU regulatory submissions	Achieved **EU**	

As of March 31, 2022, barring unforeseen events. For abbreviations see slide 53.